Action potential alternans in the right ventricular outflow tract in a patient with asymptomatic Brugada syndrome.

A 71-year-old man with frequent ventricular premature contractions after right hip joint surgery was referred to the Cardiology Division. Twelve-lead ECG showed type II Brugada-type ECG and signal-averaged ECG showed positive ventricular late potentials. The 12-lead ECG changed to type I Brugada-type after administration of the class Ic antiarrhythmic drug, pilsicainide. Ventricular fibrillation (VF) was reproducibly induced with double premature stimuli from the right ventricular outflow tract (RVOT) at a basic cycle length (BCL) of 400 ms. Monophasic action potentials (MAPs) recorded from the RVOT at a BCL of 400 ms showed MAP alternans and VF was only induced when extrastimuli were applied after a shorter MAP of the alternans.

[1]  S. Narayan,et al.  Steep restitution of ventricular action potential duration and conduction slowing in human Brugada syndrome. , 2007, Heart rhythm.

[2]  Y. Okumura,et al.  Endocardial electrograms from the right ventricular outflow tract after induced ventricular fibrillation in patients with Brugada syndrome. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[3]  Y. Aizawa,et al.  Incidence and Initial Characteristics of Pilsicainide‐Induced Ventricular Arrhythmias in Patients With Brugada Syndrome , 2007, Pacing and clinical electrophysiology : PACE.

[4]  I. Kodama,et al.  A case of short-coupled variant of torsade de pointes characterized by spatial heterogeneity of action potential duration and its restitution kinetics , 2007, Journal of Interventional Cardiac Electrophysiology.

[5]  M. Sugimachi,et al.  Cellular basis for trigger and maintenance of ventricular fibrillation in the Brugada syndrome model: high-resolution optical mapping study. , 2006, Journal of the American College of Cardiology.

[6]  H. Morita,et al.  T wave alternans in an in vitro canine tissue model of Brugada syndrome. , 2006, American journal of physiology. Heart and circulatory physiology.

[7]  H. Morita,et al.  Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. , 2003, Journal of the American College of Cardiology.

[8]  Y. Okumura,et al.  Intravenous Administration of Class I Antiarrhythmic Drug Induced T Wave Alternans in an Asymptomatic Brugada Syndrome Patient , 2003, Pacing and clinical electrophysiology : PACE.

[9]  J. Brugada,et al.  Natural History of Brugada Syndrome: , 2003, Journal of cardiovascular electrophysiology.

[10]  H. Morita,et al.  Site‐Specific Arrhythmogenesis in Patients with Brugada Syndrome , 2003, Journal of cardiovascular electrophysiology.

[11]  Y. Aizawa,et al.  Induction of Ventricular Fibrillation in Brugada Syndrome by Site‐Specific Right Ventricular Premature Depolarization , 2002, Pacing and clinical electrophysiology : PACE.

[12]  R. Hauer,et al.  Proposed diagnostic criteria for the Brugada syndrome. , 2002, European heart journal.

[13]  S. Priori,et al.  Programmed Electrical Stimulation in Brugada Syndrome: How Reproducible Are the Results? , 2002, Journal of cardiovascular electrophysiology.

[14]  G. Breithardt,et al.  Electrophysiologic investigation in Brugada syndrome; yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats. , 2002, European heart journal.

[15]  J. Yoshikawa,et al.  Pilsicanide‐Induced Marked T Wave Alternans and Ventricular Fibrillation in a Patient with Brugada Syndrome , 2002, Journal of cardiovascular electrophysiology.

[16]  W. Shimizu,et al.  The electrophysiologic mechanism of ST-segment elevation in Brugada syndrome. , 2002, Journal of the American College of Cardiology.

[17]  W. Shimizu,et al.  Paradoxic Abbreviation of Repolarization in Epicardium of the Right Ventricular Outflow Tract During Augmentation of Brugada‐Type ST Segment Elevation , 2001, Journal of cardiovascular electrophysiology.

[18]  J. Brugada,et al.  Prognostic Value of Electrophysiologic Investigations in Brugada Syndrome , 2001, Journal of cardiovascular electrophysiology.

[19]  T. Ikeda,et al.  Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: insight into risk stratification. , 2001, Journal of the American College of Cardiology.

[20]  Y. Aizawa,et al.  Intravenous Administration of Class I Antiarrhythmic Drugs Induced T Wave Alternans in a Patient with Brugada Syndrome , 2001, Journal of cardiovascular electrophysiology.

[21]  K. Sunagawa,et al.  Effect of Sodium Channel Blockers on ST Segment, QRS Duration, and Corrected QT Interval in Patients with Brugada Syndrome , 2000, Journal of cardiovascular electrophysiology.

[22]  C. Antzelevitch,et al.  Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. , 1999, Circulation.